Absolute Return Capital’s Puma Biotechnology PBYI Stock Holding History

Absolute Return Capital’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-6,755	Closed	-$789K	–	581
2015 Q2	$789K	Buy	6,755 +1,837	+37%	+$333K	0.03%	368
2015 Q1	$1.16M	Sell	4,918 -1,193	-20%	-$255K	0.03%	384
2014 Q4	$1.16M	Buy	+6,111	New	+$1.36M	0.02%	430
2014 Q3	–	Sell	-9,363	Closed	-$618K	–	846
2014 Q2	$618K	Sell	9,363 -1,984	-17%	-$141K	0.01%	797
2014 Q1	$1.18M	Buy	+11,347	New	+$1.33M	0.02%	599

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Absolute Return Capital's PBYI Position: Q3 2015 in Review

Absolute Return Capital sold out of Puma Biotechnology (PBYI) in Q3 2015, closing a stake of 6,755 shares — an estimated $789K sold.

Absolute Return Capital first reported a position in PBYI in Q1 2014 and held it in 5 quarters. The position peaked at $1.18M in Q1 2014. 163 funds tracked by Wall St. Rank hold PBYI as of Q3 2015.

Absolute Return Capital reported no remaining Puma Biotechnology position as of Q3 2015 after selling out during the quarter.
Absolute Return Capital sold 6,755 Puma Biotechnology shares in Q3 2015, an estimated $789K.
Absolute Return Capital first reported a position in Puma Biotechnology in Q1 2014 and held it in 5 quarters.
Absolute Return Capital's Puma Biotechnology position peaked at $1.18M in Q1 2014.
163 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2015.

Based on Absolute Return Capital's 13F filing for Q3 2015, filed 13 Nov 2015.